10-K: Bioventus 2025 Annual Report: Profitability Rises Amid Strategic Shifts

Bioventus Inc. reported a significant return to net income and increased Adjusted EBITDA in 2025, driven by strategic divestitures and new product launches, despite a slight dip in overall net sales.

Summary

• Net income for the fiscal year ended December 31, 2025, was $27,274 thousand, a substantial improvement from a net loss of $47,049 thousand in 2024.
• Adjusted EBITDA increased to $116,277 thousand in 2025, up from $108,882 thousand in 2024.
• Total net sales slightly decreased by 0.9% to $568,087 thousand in 2025 from $573,280 thousand in 2024.
• U.S. Pain Treatments net sales increased by $13,301 thousand (5.7%), primarily due to volume growth in Durolane.
• U.S. Surgical Solutions net sales increased by $12,736 thousand (7.6%), driven by volume growth in Bone Graft Substitutes (BGS) and Ultrasonics.
• U.S. Restorative Therapies net sales decreased by $30,749 thousand (29.5%), mainly due to the divestiture of the Advanced Rehabilitation Business, which contributed $38,200 thousand in the prior year. This was partially offset by a $6,500 thousand increase in EXOGEN Bone Stimulation System sales.
• International net sales decreased by $481 thousand (0.7%), also impacted by the Advanced Rehabilitation Business divestiture ($7,300 thousand in prior year sales), but partially offset by growth in Durolane and Ultrasonics.
• Gross profit remained stable at $388,157 thousand in 2025, with gross margin improving to 68.3% from 67.7% in 2024.
• Selling, general and administrative expenses decreased by $29,772 thousand (8.7%), largely due to lower compensation costs and a reduction in shareholder litigation costs.
• Research and development expense decreased by $1,838 thousand (13.2%) due to project completions and lower consulting expenses.
• The company refinanced its debt with a new 2025 Credit Agreement, providing a $300,000 thousand term loan and a $100,000 thousand revolving credit facility, expected to save $2,000 thousand in annual interest expense.
• FDA 510(k) clearances were received in July 2025 for TalisMann and StimTrial, expanding the Peripheral Nerve Stimulation (PNS) portfolio.
• The XCELL PRP System was fully launched in the U.S. orthopedic and sports medicine markets in August 2025.
• The Advanced Rehabilitation Business was divested on December 31, 2024, generating $24,700 thousand in cash proceeds, used to repay $20,000 thousand in long-term debt.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by significant improvements in profitability and strategic debt refinancing, despite a slight dip in overall net sales due to divestitures. The successful FDA clearances for new products and focused growth strategy are strong indicators for future performance, though ongoing legal proceedings and market competition warrant continued monitoring.

Positives

• Achieved a net income of $27,274 thousand in 2025, a significant turnaround from a net loss of $47,049 thousand in 2024.
• Adjusted EBITDA increased by 6.8% to $116,277 thousand in 2025, demonstrating improved operational performance.
• Successfully refinanced debt with the 2025 Credit Agreement, leading to an expected $2,000 thousand in annual interest expense savings and extended debt maturity to July 2030.
• Received FDA 510(k) clearances for TalisMann and StimTrial in July 2025, expanding the innovative Peripheral Nerve Stimulation (PNS) portfolio for chronic pain management.
• Initiated full commercial launch of the XCELL PRP System in August 2025, leveraging existing sales channels for synergistic growth.
• Experienced volume growth in key product areas: Durolane (Pain Treatments) and Bone Graft Substitutes (BGS) and Ultrasonics (Surgical Solutions).
• Improved U.S. gross margin by 0.8% due to a favorable product mix within BGS and enhanced collections for the EXOGEN Bone Stimulation System.
• Reduced selling, general and administrative expenses by $29,772 thousand, partly due to lower shareholder litigation costs and compensation-related costs post-divestiture.
• Net cash from operating activities increased significantly by $35,878 thousand (92.5%) to $74,673 thousand in 2025.

Negatives

• Total net sales decreased by 0.9% year-over-year, from $573,280 thousand in 2024 to $568,087 thousand in 2025.
• Net sales from Restorative Therapies (U.S. and International) decreased significantly due to the divestiture of the Advanced Rehabilitation Business.
• International gross margin decreased by 1.3% due to product and country mix.
• Incurred a $326 thousand loss on extinguishment of debt related to the refinancing transactions.
• The revenue and specified financial performance criteria for the $20,000 thousand contingent earn-out payments from the Advanced Rehabilitation Business divestiture for fiscal year 2025 were not achieved.
• Ongoing derivative shareholder lawsuits against current and former directors and officers require significant management time and attention and may result in unfavorable outcomes.

Risks

• The 2025 Credit Agreement contains financial and operating restrictions (e.g., minimum interest coverage ratio, maximum consolidated total net leverage ratio) that could limit access to credit or require debt repayment if covenants are breached.
• Additional capital may be required to fund financial obligations and support business growth, which may involve equity or additional debt financings that could dilute existing stockholders or impose restrictive covenants.
• Failure to establish and maintain effective financial controls could lead to material weaknesses and financial misstatements, adversely affecting business and stock price.
• High dependence on a limited number of products (HA products accounted for 49% of total revenue in 2025), making the company vulnerable to changes in demand or market acceptance for these products.
• Long-term growth may be limited by the inability to develop, acquire, and commercialize new products, line extensions, or expanded indications in a competitive and rapidly changing industry.
• Failure to properly manage growth or scale business processes, systems, or data management could lead to disruptions, delays, and increased costs.
• Reliance on a limited number of third-party manufacturers for certain products and critical components poses risks of supply disruptions, quality issues, and increased costs.
• Implementation of processing and billing system changes by payers may lead to unexpected increases in rebate claims, potentially impacting financial results.
• Inability to achieve and maintain adequate levels of coverage and/or reimbursement for products (e.g., TalisMann, PRP) could severely hinder commercial success.
• Consolidation in the healthcare industry may lead to demand for price concessions or exclusion from supplier lists by group purchasing organizations (GPOs) or third-party payers.
• Difficulty in completing proposed acquisitions or successfully integrating them, or not realizing anticipated benefits from business divestitures, could adversely affect operations.
• Pricing pressure from competitors or hospitals may affect the ability to sell products at profitable prices.
• Failure to successfully enter into purchasing contracts for Surgical Solutions products or engage in international contract bidding processes could decrease sales.
• The proposed down-classification of non-invasive bone growth stimulators (like EXOGEN) by the FDA could increase competition and reduce reimbursement amounts.
• Reclassification of HA products from medical devices to drugs by the FDA could negatively impact marketing and require costly additional clinical studies.
• Inability to attract, retain, and motivate senior management and other highly qualified personnel could adversely affect business and strategic plans.
• Risk of product liability claims, which could be expensive, divert management attention, harm reputation, and potentially exceed insurance coverage.
• Actual, attempted, or perceived breaches of security, unauthorized access, cyberattacks, or other incidents could result in material business loss, legal liability, or reputational harm.
• Exposure to economic, political (including international tariffs), regulatory, and currency risks associated with international sales and operations.
• Risk of enforcement action for improper claims submission practices, leading to audits, denials, and significant penalties.
• The FDA regulatory process is expensive, time-consuming, and uncertain, with failure to obtain and maintain required clearances and approvals preventing product commercialization.
• Interim, top-line, and preliminary data from clinical trials may change, potentially harming business prospects and stock price.
• Risk of enforcement action for improper marketing or promotion of products, including off-label use, leading to fines and sanctions.
• Products may cause or contribute to adverse medical events requiring FDA reporting, with failure to report leading to sanctions.
• Reliance on third parties to conduct clinical studies and preclinical development, with their failure to perform impacting regulatory clearance and commercialization.
• Healthcare regulatory reform and cost containment proposals may affect the ability to sell products profitably.
• Failure to meet Medicare accreditation and surety bond requirements or DMEPOS supplier standards could adversely affect business.
• Operations involve hazardous and toxic materials, requiring compliance with environmental, health, and safety laws, which can be expensive.
• Dependence on licensed technologies, with any loss of rights preventing product sales.
• As a holding company, dependence on distributions from BV LLC to pay taxes and expenses, including under the Tax Receivable Agreement (TRA), which may be subject to limitations.
• Dilution of Class A common stockholders upon exchange of LLC Interests and potential adverse effect on market price from resale of such shares.
• Loss of emerging growth company status by December 31, 2026, will increase reporting requirements and associated expenses.

Future Outlook

The company plans to continue strengthening its leading positions in core markets (HA, BGS, Fracture Care) through targeted account execution, which will fund expansion in Ultrasonics and international businesses, and growth in emerging PNS and PRP markets. Full commercial launches of StimTrial and TalisMann are planned for early 2026. The company aims to establish BoneScalpel as a standard of care for spine applications and expand the neXus platform into neurosurgery and general surgery. International business will focus on high-growth opportunities and strategic expansion into new markets. Selling, general and administrative expenses are expected to decline as a percentage of net sales over time, while research and development expenses are expected to vary from low to mid-single digits as a percentage of net sales with new product introductions and line extensions. The company expects to remain in compliance with financial covenants under the 2025 Credit Agreement for the next twelve months.

Management Comments

• "With TalisMann and StimTrial now FDA-cleared, we offer a comprehensive PNS portfolio that empowers physicians to potentially treat a broader spectrum of patients—from initial assessment to long-term therapy—with greater confidence and flexibility. This development also reinforces our commitment to delivering non-opioid, minimally invasive therapies designed to address real-world clinical needs."

Industry Context

StockSavvy.ai notes Bioventus's strategic pivot towards core musculoskeletal solutions and emerging technologies like Peripheral Nerve Stimulation (PNS) and Platelet-Rich Plasma (PRP) aligns with broader healthcare trends emphasizing specialized, high-value interventions and non-opioid pain management. The company's focus on expanding its Ultrasonics platform into diverse surgical specialties also reflects a move towards versatile, precision-based medical devices. However, the medical device industry remains intensely competitive and subject to significant pricing pressures and evolving reimbursement policies, as highlighted by the impact of CMS changes on HA products and the proposed down-classification of bone growth stimulators. The company's ability to navigate these regulatory and competitive landscapes will be crucial for sustained growth.

Management Changes

Corporate Governance

Legal Proceedings

• A securities class action lawsuit (Ciarciello v. Bioventus Inc.) alleging violations of Sections 10(b) and 20(a) of the Exchange Act was settled for $15,250 thousand in December 2024, with the company incurring $51 thousand in net litigation costs in 2025.
• Multiple derivative shareholder lawsuits (Grogan, Sanderson, Vince, Hyung) are pending against current and former directors and officers, generally alleging similar misconduct as the Ciarciello case, with some cases consolidated and settlement discussions ongoing.
• The company believes the claims in the pending derivative matters lack merit and intends to defend itself vigorously.

Related Party Transactions

• The company is a party to a Tax Receivable Agreement (TRA) with the Continuing LLC Owner (Smith & Nephew, Inc.), requiring cash payments equal to 85% of certain realized tax benefits from increases in BV LLC's tax basis and other tax benefits.
• The Original LLC Owners control approximately 42% of the combined voting power of common stock, influencing corporate management and affairs.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity financings or exchange of LLC Interests, and the market price of Class A common stock could be volatile due to various factors including litigation outcomes and competitive pressures. Original LLC Owners retain significant voting influence.
• Employees: Restructuring plan in November 2025 involved elimination of several positions and consolidation of administrative functions, leading to severance costs. Equity-based compensation plans are used to attract, retain, and motivate personnel.
• Customers: Product availability and pricing may be affected by supply chain issues, competition, and changes in reimbursement policies. New product launches (PNS, PRP) aim to address patient needs and expand treatment options.
• Suppliers: Reliance on a limited number of third-party manufacturers for key products and components creates supply chain risks. The company works with suppliers to manage forecasts and minimum purchase requirements.
• Creditors: The 2025 Credit Agreement imposes financial and operating covenants, which the company expects to remain in compliance with, but non-compliance could harm liquidity. Interest rate swaps are used to mitigate floating-rate debt risk.

Next Steps

• Initiate full commercial launches of StimTrial and TalisMann in early 2026.
• Continue investment in new emerging technologies and further develop and expand the Ultrasonics platform business.
• Accelerate market penetration of BoneScalpel in spinal surgery through increased surgeon education and awareness.
• Leverage the neXus platform to expand into additional specialties like neurosurgery and general surgery.
• Strategically grow international markets by focusing on high-growth opportunities and selectively expanding to new markets.
• Update government pricing compliance and reporting processes to comply with new BFSF requirements from the CMS Final Rule.
• Negotiate applicable contracts with customers to comply with the CMS Final Rule regarding BFSFs.

Key Dates

Recommendation

While Bioventus demonstrated a strong turnaround to net income and increased Adjusted EBITDA in 2025, driven by strategic divestitures and debt refinancing, the overall net sales experienced a slight decline. The successful FDA clearances for new PNS products and the launch of the PRP system are positive growth drivers. However, the company faces ongoing derivative shareholder lawsuits, significant competition in the medical device industry, and potential impacts from evolving healthcare reimbursement policies. The 'hold' recommendation reflects the balanced view of these positive developments against the inherent risks and the need for further observation of sustained growth and successful navigation of competitive and regulatory challenges.

Keywords

Medical Devices, Musculoskeletal, Pain Treatments, Surgical Solutions, Restorative Therapies, Hyaluronic Acid, HA, Peripheral Nerve Stimulation, PNS, Platelet-Rich Plasma, PRP, Bone Graft Substitutes, Ultrasonics, Fracture Care, EXOGEN, Durolane, GELSYN-3, SUPARTZ, StimRouter, TalisMann, StimTrial, XCELL PRP System, BoneScalpel, neXus, SonicOne, OSTEOAMP, SIGNAFUSE, PUREBONE, Reficio DBM, FDA Clearance, SEC Filing, 10-K, Financial Performance, Debt Refinancing, Corporate Governance, Risk Management, Healthcare Industry, Biotechnology, Orthopedics, Neurosurgery, Compliance, Intellectual Property, Cybersecurity